Sickle Cell Disease Plasma

Sickle Cell Disease Plasma for Hemoglobinopathy and Vascular Biology Research

Sickle Cell Disease Plasma is collected from IRB-consented donors clinically diagnosed with sickle cell disease (SCD) and processed within one day of collection to preserve labile analytes such as cell-free hemoglobin, cytokines, proteins, and metabolites. Cryopreserved and available in custom aliquots, this human plasma supports research into hemolysis, endothelial dysfunction, inflammation, and coagulation activation. Research Use Only (RUO).

Molecular Basis and Why Plasma

• Sickle cell disease is a monogenic disorder caused by a point mutation in HBB, the beta-globin gene, producing sickle hemoglobin (HbS) rather than normal adult hemoglobin.
• On deoxygenation, HbS polymerizes and deforms the red cell, driving chronic hemolysis and vaso-occlusion; clinical severity is modified by co-inherited alpha-thalassemia and by fetal hemoglobin (HbF) levels.
• Intravascular hemolysis releases cell-free hemoglobin and heme into plasma, depleting haptoglobin and hemopexin and consuming nitric oxide, which contributes to endothelial dysfunction and a vasculopathic phenotype.
• Plasma is the correct matrix for these soluble hemolytic markers, and for lactate dehydrogenase, bilirubin, arginine and ornithine metabolites, and soluble adhesion molecules.
• SCD is also a chronic inflammatory and prothrombotic state, so plasma supports cytokine, complement, and coagulation-activation analyses.
• Because plasma is acellular, it is well suited to biomarker and pharmacodynamic work that must be independent of red cell or leukocyte handling artifacts.

Donor Stratification Available

• Genotype where documented: HbSS, HbSC, or HbS/beta-thalassemia
• Disease-modifying therapy: hydroxyurea, voxelotor, crizanlizumab, L-glutamine, or untreated
• Transfusion history and chronic transfusion status
• Steady state versus recent vaso-occlusive crisis or hospitalization
• Documented complications: acute chest syndrome, stroke, avascular necrosis, nephropathy, pulmonary hypertension
• Age band, sex, and self-reported race/ethnicity
• Matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed SCD donors
• Processed within one day of collection
• Cryopreserved for long-term stability
• IRB-approved protocols and electronic informed consent
• Custom aliquot volumes and anticoagulant options available upon request

De-identified Donor Data

• Verified SCD diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Genotype, transfusion, and crisis history where available
• Additional sickle cell disease-specific metadata available on request

Applications

• Hemolysis biomarker measurement, including cell-free hemoglobin, haptoglobin, and heme
• Nitric oxide and arginine metabolism studies
• Endothelial activation and soluble adhesion molecule profiling
• Cytokine, chemokine, and complement analysis in chronic inflammation
• Coagulation activation and thrombo-inflammation research
• Oxidative stress and untargeted metabolomics
• Plasma proteomics and biomarker discovery
• Pharmacodynamic and treatment-response research for disease-modifying and gene-directed therapies

Other Sickle Cell Disease Specimen Types

• Sickle Cell Disease Serum
• Sickle Cell Disease Whole Blood
• Sickle Cell Disease PBMC
• Sickle Cell Trait Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Sickle Cell Disease Plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human plasma page.